Galapagos NV - Asset Resilience Ratio

Latest as of September 2025: 85.02%

Galapagos NV (GXEA) has an Asset Resilience Ratio of 85.02% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GXEA total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

€2.99 Billion
≈ $3.49 Billion USD Cash + Short-term Investments

Total Assets

€3.51 Billion
≈ $4.11 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Galapagos NV's Asset Resilience Ratio has changed over time. See Galapagos NV shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Galapagos NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Galapagos NV worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €2.99 Billion 85.02%
Total Liquid Assets €2.99 Billion 85.02%

Asset Resilience Insights

  • Very High Liquidity: Galapagos NV maintains exceptional liquid asset reserves at 85.02% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Galapagos NV Industry Peers by Asset Resilience Ratio

Compare Galapagos NV's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Galapagos NV (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Galapagos NV.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 73.83% €3.05 Billion
≈ $3.57 Billion
€4.14 Billion
≈ $4.84 Billion
-6.90pp
2023-12-31 80.73% €3.52 Billion
≈ $4.11 Billion
€4.36 Billion
≈ $5.09 Billion
+4.99pp
2022-12-31 75.74% €3.59 Billion
≈ $4.19 Billion
€4.73 Billion
≈ $5.53 Billion
+28.18pp
2021-12-31 47.56% €2.47 Billion
≈ $2.89 Billion
€5.19 Billion
≈ $6.07 Billion
-5.37pp
2020-12-31 52.93% €3.03 Billion
≈ $3.54 Billion
€5.72 Billion
≈ $6.68 Billion
-11.65pp
2019-12-31 64.58% €3.92 Billion
≈ $4.58 Billion
€6.07 Billion
≈ $7.09 Billion
--
pp = percentage points

About Galapagos NV

F:GXEA Germany Biotechnology
Market Cap
$1.83 Billion
€1.57 Billion EUR
Market Cap Rank
#6600 Global
#963 in Germany
Share Price
€23.80
Change (1 day)
-1.65%
52-Week Range
€22.40 - €31.40
All Time High
€246.00
About

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more